Evidence Table M1. Articles/arms for class ANTI-ANDROGEN.

Comp-Trial		TARGET HEADING Treatment	Dose, route, frequency	*Comments, ancillary treatment*	COMPARATOR Treatment	Dose, route, frequency	*Comments, ancillary treatment*	Outcome Table(s)
M.01.01	**141**	**Cyproterone**	20 mg topical qhs.	*Applied with calibrated pipette.*	**Vehicle**	No dose information		Continuous
M.01.02	**245**	**Ethinyl estradiol**	0.05 mg oral qd.	*Combination pill is taken qd x 21 days, then 7 days off.*	**Minocycline hydrochloride**	50 mg oral bid.		Continuous Discrete
		Cyproterone	2 mg oral qd.					
M.01.03	**137**	**Placebo**	No dose information.	*Cyproterone + ee: 21 days on then 7 days off.*	**Tetracycline**	500 mg oral (28d)		Continuous Discrete
		Cyproterone	2 mg oral qd.		**Placebo**	No dose information		
		Ethinyl estradiol	0.05 mg oral qd.					
M.01.04	**141**	**Cyproterone**	2 mg oral qd.	*OCP schedule: 2ld pills; 7d placebo.*	**Cyproterone**	20 mg topical qhs.	*Applied with calibrated pipette.*	Continuous
		Ethinyl estradiol	0.035 mg oral qd.					
M.01.05	**48**	**Ethinyl estradiol**	0.05 mg oral qd.	*Frequency was not explicitly specified but presumably was qid.*	**Ethinyl estradiol**	0.035 mg oral qd.		Continuous Discrete
		Cyproterone	2 mg oral qd.		**Cyproterone**	2 mg oral qd.		
		Ethinyl estradiol	0.05 mg oral qd.	*Frequency was not explicitly specified but presumably was qid.*	**Ethinyl estradiol**	0.03 mg oral qd.		Continuous Discrete
		Cyproterone	2 mg oral qd.		**Levonorgestrel**	150 mg oral qd.		
	66	**Ethinyl estradiol**	0.05 mg oral qd.		**Ethinyl estradiol**	0.035 mg oral qd.		Continuous Discrete
		Cyproterone	2 mg oral qd.		**Cyproterone**	2 mg oral qd.		
	117	**Ethinyl estradiol**	0.05 mg oral qd.	*Cycle 21 days on treatment and 7 days no treatment; treatment began day 5 of menstrual cycle.*	**Ethinyl estradiol**	0.035 mg oral qd.	*Cycle 21 days on treatment and 7 days no treatment; treatment began day 5 of menstrual cycle.*	Continuous
		Cyproterone	2 mg oral qd.		**Cyproterone**	2 mg oral qd.		
M.01.06	**237**	**Ethinyl estradiol**	0.05 mg oral qd.	*Combo taken from days 5 - 25 of the cycle.*	**Ethinyl estradiol**	0.05 mg oral qd.	*Cyproterone was taken from days 5-14 of cycle inclusive ee was taken from days 5-25 of cycle inclusive. Followed reversed sequential regime of*	Continuous Discrete
		Cyproterone	2 mg oral qd.		**Cyproterone**	0.05 mg oral qd.		

"(M)" indicates that data are found on the Multi-Arm tables.

Comp-Trial		TARGET HEADING			COMPARATOR			Outcome Table(s)
		Treatment	Dose, route, frequency	*Comments, ancillary treatment*	Treatment	Dose, route, frequency	*Comments, ancillary treatment*	
							Hammmerstein et al (1975).	
M.01.07	**55**	**Ethinyl estradiol** **Desogestrel**	0.03 mg oral qd. 150 mg oral qd.	*21 days tablets; 7 days no tablets.*	**Ethinyl estradiol** **Cyproterone**	0.05 mg oral qd. 2 mg oral qd.	*21 days tablets; 7 days no tablets.*	Continuous Discrete
	87	**Ethinyl estradiol** **Cyproterone**	35 mg oral qd. 2 mg oral qd.	*21 days: 2.0 mg cyproterone + 35 mg ee; 7 days: no treatment.*	**Ethinyl estradiol** **Desogestrel**	0.035 mg oral qd. No dose information	*7 days: 0.025 mg desogestrol + 0.040 mg ee; 15 days: 0.125 mg desogestrol + 0.030 mg ee; 6 days: no treatment.*	Continuous Discrete
	103	**Ethinyl estradiol** **Cyproterone**	0.035 mg oral qd. 2 mg oral qd.	*618 cycles; started day 1 of menstrual cycle; no definition of cycle.*	**Desogestrel** **Ethinyl estradiol**	0.15 mg oral qd. 0.03 mg oral qd.	*618 cycles; started day 1 of menstrual cycle; no definition of cycle.*	Discrete
M.01.08	**48**	**Ethinyl estradiol** **Cyproterone**	0.035 mg oral qd. 2 mg oral qd.		**Ethinyl estradiol** **Levonorgestrel**	0.03 mg oral qd. 150 mg oral qd.		Continuous Discrete
M.01.09	**237**	**Ethinyl estradiol** **Cyproterone**	0.05 mg oral qd. 0.05 mg oral qd.	*Cyproterone was taken from days 5-14 of cycle inclusive ee was taken from days 5-25 of cycle inclusive. Followed reversed sequential regime of Hammmerstein et al (1975).*	**Ethinyl estradiol** **Placebo** **Norethisterone**	0.05 mg oral qd. No dose information 1 mg oral qd.	*Placebo to resemble (cpa 50 mg tablets); combo preparation of norethisterone acetate 1 mg + ee 50 mg taken days (5-25) of the cycle -inclusive and placebo taken from days 5-14 inclusive.*	Continuous Discrete
M.02.01	**225**	**Desogestrel** **Ethinyl estradiol**	0.15 mg oral qd. 0.03 mg oral qd.	*Qd x 9 cycles of 21 days each, with a 7 day treatment.*	**Gestodene** **Ethinyl estradiol**	0.075 mg oral qd. 0.03 mg oral qd.	*Qd x 9 cycles of 21 days each, with a 7 day treatment.*	Continuous Discrete
M.02.02	**263**	**Ethinyl estradiol** **Desogestrel**	0.03 mg oral () 0.15 mg oral ()		**Ethinyl estradiol** **Levonorgestrel**	0.03 mg oral () 0.15 mg oral ()		Discrete
	264	**Ethinyl estradiol** **Desogestrel**	0.03 mg oral qd. 0.15 mg oral qd.		**Ethinyl estradiol** **Levonorgestrel**	0.03 mg oral qd. 0.15 mg oral qd.		Continuous

"(M)" indicates that data are found on the Multi-Arm tables.

Comp-Trial		TARGET HEADING			COMPARATOR			Outcome Table(s)
		Treatment	Dose, route, frequency	*Comments, ancillary treatment*	Treatment	Dose, route, frequency	*Comments, ancillary treatment*	
M.03.01	**132**	**Spironolactone**	100 mg oral (can't say)		**Placebo**	No dose information		(M)
	249	**Spironolactone**	200 mg oral qd.	*Following by placebo in second half of study.*	**Placebo**	No dose information	*Followed by spironolactone in second half of study.*	Continuous Discrete
M.04.01	**2**	**Delta-0.2%-chlormadione**	0.2 % topical bid.		**Vehicle**	No dose information		Discrete
M.04.02	**2**	**Delta-5%-chlormadione**	5 mg topical bid.	*1/4 inch of cream applied each application = 5 mg.*	**Vehicle**	No dose information		Discrete
M.04.03	**2**	**Delta-0.2%-chlormadione**	0.2 % topical bid.		**Delta-5%-chlormadione**	5 mg topical bid.	*1/4 inch of cream applied each application = 5 mg.*	Discrete
M.04.04	**19**	**16-epiestriol-3-allyl ether**	15 mg oral (qd for 4 weeks, bid for 4 weeks, tid for 4 weeks)	*Synthetic estrogen. Topical - varied.*	**Placebo**	15 mg oral (qd for 4 weeks, bid for 4 weeks, tid for 4 weeks)	*Topical - varied.*	Discrete
M.04.05	**295**	**Epiestriol**	2.5 mg/g topical qd.		**Vehicle**	No dose information		Discrete
M.04.06	**213**	**Inocoterone acetate**	10 % topical bid.	*Generic soap and shampoo.*	**Vehicle**	No dose information	*Generic soap and shampoo.*	Continuous Discrete
M.04.09	**218**	**Inactive drug** **Norgestimate** **Ethinyl estradiol**	No dose information. 0.18 mg oral qd. 0.035 mg oral qd.	*21 days of active treatment followed by 7 days of inactive drug: 0.0180 for 7 days; 0.215 for 7 days; 0.250 for 7 days; 0 for 7 days.*	**Placebo**	No dose information	*Color-matched tablets.*	Continuous Discrete
	280	**Norgestimate** **Ethinyl estradiol**	No dose information. 0.035 mg oral qd.	*180 mg 1-7 days; 215 mg 8-14 days; 250 mg 15-21 days.*	**Placebo**	No dose information		Continuous Discrete
M.04.10	**248**	**Quinestradol**	1 mg oral qd.		**Placebo**	No dose information	*Proprietary topical preparation containing mild antiseptic and peeling agents.*	Continuous

"(M)" indicates that data are found on the Multi-Arm tables.

Comp-Trial		TARGET HEADING			COMPARATOR			Outcome Table(s)
		Treatment	Dose, route, frequency	*Comments, ancillary treatment*	Treatment	Dose, route, frequency	*Comments, ancillary treatment*	
M.04.11	**271**	**Serum gonadotrophin**	58 unit oral ()	*100 u qd X 2w; then 50 u qd X 4 w; then 25 u qod x 6 w. Cetrimide®, ultra-violet light, tetracycline.*	**Placebo**	58 units oral qd.	*Cetrimide®, ultra-violet light, tetracyline.*	Discrete
N.06.01	**156**	**Cimetidine**	1.6 g oral (*)	*1.6 g per day in "divided dose" - doesn't say how many.*	**Cimetidine**	1.6 g oral (*)	*1.6 g per day in "divided dose" - doesn't say how many.*	Continuous (M)

"(M)" indicates that data are found on the Multi-Arm tables.